Free Trial!
Today’s Best Stocks To Trade! Click Here
Sign-up for our FREE Micro Cap Stock Picks, Trading Ideas, Commentary and Alerts at http://www.microcapopportunity.com
PLATFORMS WIRELESS INTL. CORP. (OTCPK: PLFM | Quote | Chart | News | PowerRating) Up 62.50% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=PLFM.PK
Platforms Wireless International Corporation, headquartered in Westlake Village, California, is the developer of the innovative airborne wireless communications core technology known as the Airborne Relay Communications "ARC" System Core Technology(TM). The ARC System Core Technology(TM) can provide wide area wireless telecommunications services from a High Altitude Wireless Communications System ("HAWCS(TM)") platform, using Transportable, Mobile Tall Towers and/or Transportable, Mobile Aerostats as the System delivery vehicles.
RECOM-911(TM) -- the "Rapid Response Emergency Communications System(TM)," is the Company's principal system product: a high altitude, rapid response emergency communications system that can be readily deployed to critical emergencies and natural or man-made disasters where the communications infrastructure has been compromised or completely destroyed. The System is designed to provide a transportable cellular voice, data, video and sensor communications network designed to provide cellular and interoperable radio communications facilities for emergency first responders. RECOM-911(TM) can automatically create a private, autonomous, voice, data, video, and sensor communications network by linking up to ten system units positioned up to 20 miles apart from each other. The Transportable Tower System provides up to a 15-mile radius geographical coverage (depending on terrain and line-of-sight), with a service capacity of up to 50,000 users, and it can interconnect with the PSTN via cable, fiber, and microwave or satellite link, as required.
ROSETTA-911(TM), the "Radio Open System Electronic Translation and Transmission Architecture" system, provides advanced radio communications interoperability between VHF, UHF, 800 MHz radios, including cellular and land line telephones, as well as Internet/VOIP communications connectivity. The ROSETTA-911(TM) System can operate as a portable, autonomous interoperable radio communications field station, or it can be deployed aboard a Transportable Aerostat or Tall Tower, to operate in conjunction with the RECOM-911(TM) Cellular Communications System.
Platforms Wireless believes its rapid-response High Altitude Wireless Communications Systems(TM) ("HAWCS(TM)") can provide advanced, cost-effective, voice, data, video, and sensor communications solutions for military, commercial, and critical emergency applications, particularly for natural or man-made disasters, where communications infrastructures have been compromised or completely destroyed. RECOM-911(TM) can also be used as a cost-effective commercial telecommunications solution to strategically augment and/or supplement terrestrial land-line and wireless telecommunications infrastructures, and to rapidly and profitably penetrate new market areas.
Recent PLFM News:
June 24, 2008 - Platforms Wireless Completes 6-Year Independent Audit for Issuance of Certified Financial Statements and Filing of S-1 Registration Statement
Platforms Wireless International Corporation (Pink Sheets:PLFM) (www.plfm.net) announced today that its independent auditors have completed their field work on a six-year, comprehensive audit of the company's financial statements. The independent audit required more than two years to complete, and it covers the fiscal years ended June 30, 2002 through June 30, 2007. The audit was conducted by Farber Hass Hurley LLP, a PCAOB registered accounting firm headquartered in Camarillo, California.
President Charles B. Nelson commented: "I would like to thank our auditors and everyone involved in this long and challenging process for their hard work and dedication to see this critical task completed. We expect to publish the Company's audited financial statements for the fiscal years ended June 30, 2002 through June 30, 2007 in July.
"The further independent audit of the Company's records for the current fiscal year ending June 30, 2008, as well as the publication of corresponding financial statements, should be completed by September 30, 2008."
With the completion of the Company's independent audit, management intends to file its S-1 Registration Statement and apply for listing on the OTC Bulletin Board. Management expects to file the Company's S-1 Registration Statement in the third quarter of 2008.
President Charles B. Nelson pointed out: "It is important for our shareholders to note that the Company's research and development efforts, since the Company's inception in 1992 through June 30, 2007, were costly to the bottom line, but they have produced advanced high-altitude wireless communications core technology and derivative wireless communications products for military, commercial, and emergency communications applications.
"In addition," President Charles B. Nelson concluded, "once the Company completes and files its income tax returns to reflect the audited results for these periods, we expect to have a substantial Net Operating Loss ('NOL') carry-forward benefit available to offset future income taxes on our operations."
AMERICAN HEALTHCHOICE, INC. (OTCPK: AMHI | Quote | Chart | News | PowerRating) Up 100.00% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=AMHI.PK
The Company began operations in 1994 and has since grown substantially, paying off debt, increasing revenues and constantly searching for new medical-based solutions. American HealthChoice operates as both AHC Medical and RehabCo.
The medical clinics are located throughout the Southeast USA. We presently own and operate 8 company-owned clinics and have another 35 clinics in our Affiliated Clinic Program. We recently sold a number of clinics in order to pay off debt and bolster our ability to build new revenue producing business entities. TelmedCo provides second opinions to company-owned and affiliated clinics as well as four clinics outside the Division's network.
RehabCo recently reorganized from providing spinal decompression technology to becoming a world class provider of state-of-the-art medical equipment. RehabCo's mandate and challenge is to distribute and/or manufacture "revolutionary" new medical products at a cost substantially below other similar or competing products. To that end, we are constantly searching for those medical solutions that are years ahead of the competition.
The first medical equipment product that will be brought to the market through RehabCo is The OmniBody Scan, an absolutely revolutionary and unmatched infrared imaging solution. The OmniBody Scan is a product that highlights areas of abnormality within the body and directs both the clinician and patient to those areas for further diagnosis. The infrared image is non-invasive and has no harmful side effects. An X-ray, on the other hand, has potentially very harmful side effects from radiation. One of the major health problems that the OmniBody Scan will target is breast cancer. The sensitivity of the lens allows for a body scan image and detail not yet seen in a medical infrared imaging product. RehabCo also offers "image reading" services to both the patient and clinician through licensed thermographers. For more information, please go to RehabCo website.
Recent AMHI News:
June 24, 2008 - American HealthChoice CEO Dr. J.W. Stucki Provides Company Update
American HealthChoice, Inc. (Pink Sheets: AMHI), http://www.americanhealthchoice.com, a medical services company with medical clinics in Texas and Tennessee, today, in an update for Company shareholders, said its net income for the six months ended March 31, 2008, totaled $32,300.
Net income for the second quarter ended March 31, 2008 totaled $47,300. The Company announced that patient billings from its four company-owned clinics and affiliated clinics totaled $2.5 million for the first six months of the current fiscal year.
Finally, the Company announced that it has reached agreement with its lender and debenture holders on a restructuring that will limit stock dilution. "With this restructuring, AMHI is positioned for future growth," said Dr. J.W. Stucki, Chairman and CEO. The Company said it will make cash payment of $7500 a month for the next 26 months as part of the restructuring.
Dr. Stucki said the Company will update shareholders on its telemedicine systems and its OmniBody scan in a news release soon.
American HealthChoice, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
Six months ended
December March March 2007 Q 2008 Q 2008
Patient billings-Company-owned $1,241,400 $1,215,500 $2,456,900
Provision for discount on billings 696,600 675,900 1,372,500
Net patient billings-Company-owned 544,800 539,600 1,084,400
Net retained affiliated 71,000 71,000 142,000
Net clinic billings 615,800 610,600 1,226,400
Clinic expenses 450,700 405,900 856,600
Corporate expenses 159,100 136,400 295,500
Total operating expenses 609,800 542,300 1,152,100
Operating income 6,000 68,300 74,300
Other expenses 21,000 21,000 42,000
Net income (loss) $(15,000) $47,300 $32,300
Average common shares outstanding 153,000,000 160,000,000 157,000,000
GENTA, INC. (OTCBB: GNTA | Quote | Chart | News | PowerRating) Up 31.76% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=GNTA.OB
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules.
Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
Recent GNTA News:
June 24, 2008 - Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Genta Incorporated (OTC Bulletin Board: GNTA | Quote | Chart | News | PowerRating) announced the presentation of a progress update from an ongoing Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, the Company's lead oncology product, in patients with advanced melanoma. The data were presented at a satellite investigator's meeting held in conjunction with the Adjuvant Melanoma Congress sponsored by the European Association of Dermato-Oncology (EADO) in Marseille, France on June 21, 2008.
AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from Genta's prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients identified by a biomarker who have not previously received chemotherapy. The co-primary endpoints of AGENDA are progression-free survival and overall survival. The trial is being led by the EADO in Europe and by the M.D. Anderson Cancer Center, Houston, TX in the U.S.
To date, more than one-third of the expected total number of patients have now been randomized onto the AGENDA trial. A total of 83 sites in 12 countries have been opened in Europe, the U.S., Canada, and Australia. Clinical characteristics of the first 70 patients accrued to AGENDA (not identified by treatment group) were shown to be similar to the biomarker-defined population accrued in the previous Phase 3 trial of Genasense, known as GM301. The incidence of serious adverse events in AGENDA has been somewhat lower, which probably reflects the routine use of prescribed supportive care for all patients, as well as the double-blind design of AGENDA compared with the open-label design of GM301. Target accrual of 300 patients is expected to complete in the fourth quarter of 2008, with initial data expected shortly thereafter.
About AGENDA
AGENDA is a global Phase 3, randomized, double-blind trial in patients with advanced melanoma. The study is designed to confirm certain safety and efficacy results from an antecedent randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood. Analysis of those efficacy outcomes in GM301, which were observed in 274 patients, showed the following results: Hazard Endpoint Genasense/DTIC DTIC Ratio P Overall response 20.8% 7.2% 0.002 Durable response 10.7% 2.4% 0.007 Progression-free 3.6 mos. 1.6 mos. 0.58 < 0.0001 survival, median Overall survival, 12.3 mos. 9.9 mos. 0.64 0.0009 medianA scientific article that describes efficacy and safety results from GM301 can be accessed at: http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1
About the EADO
The EADO is an independent non-profit organization dedicated to the promotion, coordination, and improvement of clinical and laboratory research activities in the field of skin cancer. The organization has an European and international membership of dermatologists, oncologists and clinical as well as basic research scientists interested in the field of dermato-oncology. EADO provides leadership by formulating and disseminating quality standards and guide-lines for diagnosis and treatment of skin cancer, and it provides direction, coordination and organizations of clinical, therapeutic, and experimental trials.
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
SILVER BUTTE MINING CO. (OTCBB: SIBM | Quote | Chart | News | PowerRating) Up 25.00% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=SIBM.OB
Recent SIBM News:
June 24, 2008 - Silver Butte to Enter Coal Industry
On June 23, 2008 Silver Butte entered into a Letter of Intent for a share exchange with Blue Arch Coal Company, a Wyoming corporation ("Blue Arch"). Blue Arch Coal Company is a privately held corporation that currently owns options to acquire four state coal leases in the Powder River Basin of Wyoming. The leases are estimated to contain 148.3 million tons of proven sub-bituminous coal reserves.
Under the terms of the proposed share exchange, at closing, each of the approximately 220,500,000 then outstanding shares of Blue Ach will be exchanged for shares of Silver Butte on a one for one basis (i.e. one share of Silver Butte will be issued in exchange for one share of Blue Arch).
Closing of the transaction is contingent upon completion of Due Diligence by each corporation and negotiation of a definitive Share Exchange Agreement which must be approved by the Board of Directors of Silver Butte and Blue Arch and by the shareholders of Blue Arch holding majority of the outstanding shares of Blue Arch Common Stock. The Share Exchange Agreement will contain, among other conditions, a requirement that prior to closing Blue Arch shall have obtained equity financing in the minimum amount of $3million. After closing of the transaction it is anticipated that there will be a 1:5 reverse split of the Silver Butte Common stock and that Silver Butte shall amend its Articles of Incorporation changing the name of the Corporation to Blue Arch Energy, Inc.
DELCATH SYSTEMS, INC. (NASD: DCTH | Quote | Chart | News | PowerRating) Up 4.35% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=DCTH
Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested with the drug melphalan in Phase III and Phase II clinical trials. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
Recent DCTH News:
June 24, 2008 - Delcath Expands Multi-Center Phase III Trial for Metastatic Melanoma
Delcath Systems, Inc. (NASDAQ: DCTH | Quote | Chart | News | PowerRating) announced today that the University of Texas Medical Branch at Galveston (UTMB), part of the University of Texas System, has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high-dose delivery of the anti-cancer agent melphalan. UTMB is the sixth center in this multi-center study testing the Delcath System.
Delcath and UTMB have entered into a clinical research agreement to conduct the Phase III National Cancer Institute (NCI) led study. Orhan S. Ozkan, MD, Associate Professor of Radiology and Director of Vascular and Interventional Radiology, will serve as the Principal Investigator of the study. On joining this study, Dr. Ozkan commented, "We are excited about being a part of this clinical trial and being the first center to offer this treatment modality to patients in this region of the US. This treatment offers tremendous promise for patients suffering from metastatic melanoma in the liver, and we are pleased to be able to offer this option to our patients."
Over the past two months, Delcath Systems has added five cancer centers to this Phase III trial, which needs fewer than sixty additional patients to reach full enrollment. On the addition of UTMB to this study, Richard Taney, President and CEO of Delcath, stated, "We continue our efforts to make this treatment option available at leading cancer centers throughout the United States. Dr. Ozkan's participation will provide patients in the southwest region of the country access to this trial and provides an important treatment option for inoperable metastatic melanoma to the liver. The interest in PHP by the physicians treating this fatal condition continues to grow and we continue working to expand the geographic availability of our technology."
The Phase III Study
The Phase III study is designed to test Delcath's proprietary PHP System for the regional delivery of melphalan to the liver to treat patients with metastatic ocular and cutaneous melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.
Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System. The Phase III study, which recently exceeded 33% enrollment, is expected to be completed in 2009, leading to an application to the US Food and Drug Administration (FDA) for commercial approval of the PHP System.
About the University of Texas Medical Branch at Galveston
UTMB is a major academic health center dedicated to improving lives through health sciences education, clinical care and biomedical research. The University has six hospitals in Galveston, 90 campus- and community-based clinics, and four schools: medical, nursing, allied health sciences, and a graduate school for biomedical sciences. UTMB is the lead institution for the Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases and is the site of the Galveston National Laboratory, one of only two national biocontainment laboratories. Last year UTMB had $156 million in research expenditures with $105 million in NIH funding. Major research and patient care initiatives include a cancer center, a transplant center, molecular cardiology, burns care, neurology and the neurosciences, infectious disease, and women's and children's health. The University is the seventh largest employer among those headquartered in the Houston/Galveston region with 12,000 employees and a $1.4 billion budget. For more information, please visit the UTMB website at http://www.utmb.edu/
TELECOMMUNICATION SYSTEMS, INC. (NASD: TSYS | Quote | Chart | News | PowerRating) Up 2.97% Yesterday
Detailed Quote: http://finance.yahoo.com/q?s=TSYS
TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS | Quote | Chart | News | PowerRating) produces wireless data communications technology solutions that require proven high levels of reliability. TCS provides wireless and VoIP E9-1-1 network-based services, secure deployable communication systems, engineered satellite-based services, and commercial location applications, like traffic and navigation, using the precise location of a wireless device. Customers include leading wireless, cable MSOs, and VoIP carriers around the world, and agencies of the U.S. Departments of Defense, State, and Homeland Security. For more information, visit www.telecomsys.com.
Recent TSYS News:
June 24, 2008 - TCS Awarded Multi-Million Dollar Contract to Provide a Private Satellite Network in Afghanistan
TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a leading provider of mission-critical wireless communications, today announced that it has been awarded a three-year, $2.4 million contract to build and implement an IP-based private satellite network that will support U.S. Department of Defense (DoD) personnel in Afghanistan.
This network, scheduled to be fully operational by mid-July, will provide voice, video, and data services in remote areas that lack terrestrial service. TCS will provide 24x7 network management and monitoring to ensure the highest network availability for the end users. TCS has a proven performance record implementing networks of this type around the world. Previously, TCS has built networks to support government agencies in South West Asia, Africa and in South America, as well as the largest private VSAT network in the Asia Pacific region for a leading U.S. banking organization.
"It is an honor and a privilege for TCS to deploy a network that will be enjoyed for off-duty use by men and women in Afghanistan," said Michael Bristol, Senior Vice President of TCS' Government Solutions Group. "Providing the technology to communicate with their loved ones back home is crucial to maintaining good morale."
TCS' Government Solutions Group began with the company's founding in 1987 as a government systems integrator. Today it is a leading provider of fixed and deployable communication solutions for government customers and mobile operators requiring high reliability and security, including the U.S. Army, U.S. Air Force, U.S. Navy, Unified Combatant Commands, U.S. Department of State (DoS), U.S. Secret Service (USSS), and various U.S. intelligence agencies. As a result of its extensive R&D effort, TCS has developed a suite of products under the SwiftLink brand, designed for highly reliable, "on-the-quick-halt and on-the-move" secure communications for the DoD and other federal agencies. TCS' deployable communications systems and fixed site earth stations enable communications to some of the world's most hostile and remote locations.
About The Micro Cap Opportunity.
The Micro-Cap Opportunity is an online Newsletter that provides actionable stock picks, alerts and commentary for astute speculators in Micro Cap (company's with market capitalizations of less than $250 Million) and Nano Cap stocks (company's with market capitalizations of less than $50 Million), commonly known as "penny stocks". Our goal is to bring the very best speculative trading and investing ideas and opportunities to our subscribers' e-mail boxes on a daily and weekly basis. We publish our Daily Before the Bell' Newsletter to our subscribers by 8:45 AM EST, which is then sent out on M2 Presswire as the equity markets open. The Before the Bell Newsletter highlights our On the Radar' Micro & Nano Cap stocks plays for that day. To feature a company on our web site or in our daily Newsletter, please contact our publisher, J. Cooper via email at info@microcapopportunity.com.
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The Micro Cap Opportunity employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold The Micro Cap Opportunity, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities.
Disclosure: The Micro Cap Opportunity has not been compensated to mention any of the companies in this press release. The Micro Cap Opportunity has received compensation for other Featured Picks on the web site. For a complete list of disclosures go to http://www.microcapopportunity.com/disclaimer.php The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. The Micro Cap Opportunity encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and The Micro Cap Opportunity makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The Micro Cap Opportunity and its affiliates are not registered investment advisors or a broker dealers. The Micro Cap Opportunity has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. The Micro Cap Opportunity also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. The Micro Cap Opportunity makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through The Micro Cap Opportunity. The Micro Cap Opportunity owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
The Micro Cap Opportunity and newsletter may provide hyperlinks to third party websites or access to third party content. The Micro Cap Opportunity does not control, endorse, or guarantee content found in such sites. You agree that The Micro Cap Opportunity is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that The Micro Cap Opportunity shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
CONTACT: J. Cooper, Editor & Publisher, The Micro Cap Opportunity e-mail: info@microcapopportunity.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
